Tracking of low disease burden in multiple myeloma: Using mass spectrometry assays in peripheral blood Journal Article


Authors: Chapman, J. R.; Thoren, K. L.
Article Title: Tracking of low disease burden in multiple myeloma: Using mass spectrometry assays in peripheral blood
Abstract: Efforts over the last 5 years have demonstrated that it is technically feasible to detect low levels of monoclonal proteins in peripheral blood using mass spectrometry. These methods are based on the fact that an M-protein has a specific amino acid sequence, and therefore, a specific mass. This mass can be tracked over time and can serve as a surrogate marker of the presence of clonal plasma cells. This review describes the use of mass spectrometry to detect M-proteins in multiple myeloma to date, identifies the challenges of using this biomarker, and describes potential strategies to overcome these challenges. We discuss the work that must be done for these techniques to be incorporated into clinical practice for tracking of low disease burden in multiple myeloma. © 2020 Elsevier Ltd
Keywords: review; clinical practice; reproducibility; mass spectrometry; biological marker; multiple myeloma; immunoglobulin; standardization; plasma cell; correlation analysis; amino acid sequence; minimal residual disease; blood analysis; half life time; matrix assisted laser desorption ionization time of flight mass spectrometry; m protein; clinical laboratory; peripheral blood; triple quadrupole mass spectrometry; disease burden; human; priority journal; time of flight mass spectrometry; fourier transform ion cyclotron resonance mass spectrometry
Journal Title: Best Practice and Research: Clinical Haematology
Volume: 33
Issue: 1
ISSN: 1521-6926
Publisher: Elsevier Inc.  
Date Published: 2020-03-01
Start Page: 101142
Language: English
DOI: 10.1016/j.beha.2020.101142
PUBMED: 32139008
PROVIDER: scopus
DOI/URL:
Notes: Review -- Export Date: 1 April 2020 -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Katie Lynn Thoren
    19 Thoren